October 21, 2018
Not intended for U.S. and UK Media - ESMO 2018 Congress (European Society for Medical Oncology)
Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor types
